Ottimizzazione dell'approccio diagnostico ai test allergici alle cefalosporine (DACAT)
Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
- Droga: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing
- Droga: Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge
- Droga: Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge
- Droga: Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge
- Droga: Amoxicillin double-blind placebo-controlled drug challenge
Descrizione dettagliata
Background:
In the United States, beta-lactam antibiotics are the leading cause of allergic reactions. Cephalosporin antibiotics, in particular, are the most common cause of drug-induced anaphylaxis and perioperative allergy. For penicillin allergy, the mechanism of allergy and the antigenic determinants are known; validated penicillin skin testing followed by drug challenge has a 100% negative predictive value to exclude an immunoglobulin (Ig)E-mediated reaction. For cephalosporin allergy, the antigenic determinants and mechanism are not known, and skin testing is not validated. The diagnostic test characteristics of skin testing with native cephalosporins remain unclear with no sensitivity nor specificity reported. Although beta-lactam cross-reactivity has been hypothesized to be from the similarity of the R1 side chains, rather than the beta-lactam ring, cross-reactivity estimates among beta-lactams vary. Furthermore, it is not known whether the variance in cross-reactivity is due to true allergy versus sensitization based on positive skin testing, given that drug challenges were not performed on skin-test-positive patients. While an IgE mechanism is assumed for cephalosporin allergy and supported by skin testing that has been positive, the biology has yet to be characterized, and some cephalosporin anaphylaxis can occur on the first exposure, which is inconsistent with an IgE mechanism. Given the complexity of cephalosporin structures and potential epitopes, there may be several distinct biologic pathways involved in cephalosporin allergy. Future diagnostics in cephalosporin allergy are reliant on determination of these biological pathways and finding key haptens.
Aims:
Current national practice guidelines related to cephalosporin allergy assessment are conditional and based on low-quality evidence. The overall goal is to identify the optimal diagnostic approach to cephalosporin allergy and determine beta-lactam cross-reactivity, while discovering the mechanism and antigenic determinants of cephalosporin allergy to advance future diagnostics. The investigators will do this through a clinical trial that will generate empirical evidence through novel trial procedures, double-blind skin testing, and double-blind placebo-controlled drug challenges. Specific aims are: 1) To determine the optimal approach to cephalosporin allergy evaluation; 2) To assess beta-lactam cross-reactivity in cephalosporin-allergic individuals; and 3) To investigate the antigenic determinants and mechanism of cephalosporin allergy.
Study Overview:
Enrolled and consented subjects will attend Visit 1 for baseline screening, sample collection, double-blind skin testing to a beta-lactam panel, and a double-blind placebo-controlled challenge to their culprit cephalosporin antibiotic. Results of the culprit cephalosporin challenge determine subject's study timeline. Subjects confirmed as non-allergic to their culprit cephalosporin will return for the End-of-Study Visit for venipuncture and blood collection, ending their participation in the study. Subjects who are confirmed as allergic to their culprit at Visit 1 will return for three additional visits; Visits 2 and 3 will include double-blind placebo-controlled challenges to a similar side chain and dissimilar side chain cephalosporin (as compared to the side chain of their culprit) to assess cross-reactivity. The order of these two challenges is randomized between Visit 2 and 3, and the order of whether a similar or dissimilar side chain cephalosporin is challenged first (in Visit 2) differentiates the comparator arms of this study. In Visit 4, subjects from both comparator arms will undergo a double-blind placebo-controlled challenge to a penicillin to assess cross-reactivity between cephalosporins and penicillins. After completion of this penicillin challenge, confirmed-allergic participants will return for an End-of-Study Visit. This visit will mark the end of their participation in the study. Venipuncture and sample collection will occur at each visit.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Kell Lopez, BS
- Numero di telefono: 6177320589
- Email: klopez5@bwh.harvard.edu
Backup dei contatti dello studio
- Nome: Cara Yelverton, BSc, PhD
- Numero di telefono: 6177242415
- Email: cyelverton@mgh.harvard.edu
Luoghi di studio
-
-
Arizona
-
Scottsdale, Arizona, Stati Uniti, 14607
- Reclutamento
- Mayo Clinic Arizona
-
Contatto:
- Alexei Gonzalez-Estrada, MD
- Numero di telefono: 904-953-2451
- Email: gonzalez.alexei@mayo.edu
-
Contatto:
- Renee Nunez, BS
- Numero di telefono: 480-574-1826
- Email: Nunez.Renee@mayo.edu
-
Investigatore principale:
- Alexei Gonzalez-Estrada, MD
-
-
California
-
San Francisco, California, Stati Uniti, 94143
- Reclutamento
- University of California, San Francisco
-
Contatto:
- Monica Tang, MD
- Numero di telefono: 415-514-8044
- Email: dacat@ucsf.edu
-
Contatto:
- Jade Vi
- Numero di telefono: 415-476-1783
- Email: dacat@usf.edu
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Reclutamento
- Massachusetts General Hospital
-
Contatto:
- Aleena Banerji, MD
- Numero di telefono: 6177263850
- Email: ABANERJI@mgh.harvard.edu
-
Investigatore principale:
- Aleena Banerji, MD
-
Contatto:
- Noah Im, BS
- Numero di telefono: 617-726-2974
- Email: noim@mgh.harvard.edu
-
-
New York
-
Rochester, New York, Stati Uniti, 14621
- Reclutamento
- Rochester General Hospital
-
Contatto:
- Allison C Ramsey, MD
- Numero di telefono: 585-922-8350
- Email: allison.ramsey@rochesterregional.org
-
Contatto:
- Dawn Shefflin, RN
- Numero di telefono: 585-922-8314
- Email: dawn.sheflin@rochesterregional.org
-
Investigatore principale:
- Allison C Ramsay, MD
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University Medical Center
-
Contatto:
- Elizabeth Phillips, MD
- Numero di telefono: 6153100339
- Email: elizabeth.j.phillips@vumc.org
-
Investigatore principale:
- Elizabeth Phillips, MD
-
Contatto:
- April O'Connor, RN
- Numero di telefono: 615-957-6057
- Email: april.oconnor@vumc.org
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- University of Texas Southwestern Medical Center
-
Contatto:
- David A Khan, MD
- Numero di telefono: 214-406-5119
- Email: Dave.Khan@UTSouthwestern.edu
-
Investigatore principale:
- Dave Khan, MD
-
Contatto:
- Sophia Lopez, BS
- Numero di telefono: 469-444-0531
- Email: Sophia.Lopez@UTSouthwestern.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 18-70 years old.
- Reaction history consistent with a potential immediate hypersensitivity reaction (pruritus, urticaria, erythema, angioedema, bronchospasm, wheezing, shortness of breath, anaphylaxis, or hypotension) to cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime.
- English speaking or non-English speaking with translation services available.
Exclusion Criteria:
- Severe concomitant medical condition (e.g., unstable coronary artery disease, congestive heart failure, severe chronic obstructive pulmonary disease, poorly controlled asthma, chronic renal failure, cirrhosis, or end-stage liver disease.)
- History of Clostridioides difficile infection
- Chronic spontaneous urticaria or systemic mastocytosis
- Incident reaction required cardiopulmonary resuscitation
- Reaction to 2 or more cephalosporin antibiotics
- Active infection or antibiotic treatment within 7 days
- Treatment with systemic antihistamines or corticosteroids within 7 days
- Treatment with omalizumab or dupilumab within 60 days
- Significant immunosuppression
- Treatment with a beta-blocker or ACE inhibitor within 7 days
- Use of investigational drugs within 60 days of participation
- Anaphylaxis in the last 30 days
- Penicillin anaphylaxis within the past year confirmed with positive penicillin skin tests
- Prison or jail inmates, pregnant women, severe cognitive impairment
- Current, diagnosed, mental illness or current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements
- Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.
- Inability or unwillingness of a participant to give written informed consent or comply with study protocol
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Similar cephalosporin first
In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a similar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a dissimilar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms. |
Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), Pre-PEN (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), Pre-PEN (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls. After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well. |
|
Sperimentale: Dissimilar cephalosporin first
In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a dissimilar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a similar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms. |
Percutaneous and intradermal skin testing will be performed in all participants. Concentrations for percutaneous testing; cefazolin (330 mg/ml), cefuroxime (90 mg/ml), ceftazidime (100 mg/ml), ceftriaxone (100 mg/ml), cefepime (200 mg/ml), pre-pen (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (6 mg/ml). Concentrations for the first intradermal testing; cefazolin (3.3mg/ml), cefuroxime (1 mg/ml), ceftazidime (1 mg/ml), ceftriaxone (1 mg/ml), cefepime (2 mg/ml), Pre-PEN (undiluted), penicillin G (1000 U/ml), ampicillin (20 mg/ml), and histamine (0.1 mg/ml). Concentrations for the second intradermal testing; cefazolin (33mg/ml), cefuroxime (10 mg/ml), ceftazidime (10 mg/ml), ceftriaxone (10 mg/ml), cefepime (20 mg/ml), Pre-PEN (undiluted), penicillin G (10,000 U/ml), ampicillin (20 mg/ml) and histamine (0.1 mg/ml). Histamine and saline will be used as positive and negative controls. After double-blind skin testing, participants will undergo a 3-step double-blind placebo-controlled drug challenge to their culprit cephalosporin (the cephalosporin they are suspected to be allergic to, either cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime). The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that shares a similar side chain with their culprit. This will be cefepime for those allergic to ceftriaxone, cefaclor for those allergic to cephalexin, cefixime for those allergic to cefdinir, cefdinir for those allergic to cefixime, cephalexin for those allergic to cefaclor or cephadroxil, and ceftriaxone for those allergic to cefepime, cefuroxime, or cefpodoxime. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will undergo a 3-step double-blind placebo-controlled drug challenge to a cephalosporin antibiotic that has a dissimilar side chain to their culprit. This will be ceftriaxone for those allergic to cefazolin, and cefazolin for those allergic to any other cephalosporin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. Participants will optionally undergo a 3-step double-blind placebo-controlled drug challenge to Amoxicillin. The challenges are 1:1 randomized to the order of active drug versus placebo. In Step 1, participants will receive 1:1000 of a full dose of either the culprit drug or placebo, followed by a 30-minute observation period. In Step 2, participants will receive 1:50 of a full dose of either, followed by another 30-minute observation period. In Step 3, participants are administered the full dose of either agent, followed by a 60-minute observation period. The same testing process is repeated for the second challenge. The order of challenge to similar vs. dissimilar cephalosporin will be randomized as well. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of participants with confirmed culprit cephalosporin allergy
Lasso di tempo: Up to 7 weeks
|
Placebo-controlled drug challenges will be used to confirm or disprove participant's cephalosporin allergies, and the proportion of included participants with confirmed allergies will be measured. |
Up to 7 weeks
|
|
Cephalosporin skin test sensitivity and specificity
Lasso di tempo: Up to 7 weeks
|
Challenge results will be used as a reference standard to determine the sensitivity and specificity of cephalosporin skin testing. |
Up to 7 weeks
|
|
Proportion of cross-reactivity to other cephalosporins in confirmed-allergic subjects
Lasso di tempo: Up to 7 weeks
|
The proportion of participants with confirmed cross-reactivity to dissimilar/similar cephalosporins than their culprit will be determined. |
Up to 7 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Culprit cephalosporin skin test diagnostic characteristics
Lasso di tempo: Up to 7 weeks
|
The diagnostic testing characteristics of culprit cephalosporin skin tests will be evaluated, including positive predictive value (PPV), negative predictive value (NPV), and false positive rate. |
Up to 7 weeks
|
|
Cephalosporin skin test diagnostic characteristic performance differences between risk groups
Lasso di tempo: Up to 7 weeks
|
Allergy history risk will be measured using a validated Drug Allergy History Tool. The PPV, NPV, and false positive rate of skin testing will then be compared through regression modeling to show differences in diagnostic characteristic performance between high-risk and low-risk groups. |
Up to 7 weeks
|
|
Association between patient demographics and confirmed cephalosporin allergy
Lasso di tempo: Up to 7 weeks
|
Participant demographic traits will be collected and their associations with confirmed cephalosporin allergy will be presented as odds ratios with 95% confidence intervals. |
Up to 7 weeks
|
|
Association between patient allergy history and confirmed cephalosporin allergy
Lasso di tempo: Up to 7 weeks
|
A validated Drug Allergy History Tool will be used to collect participant's allergy history, and associations of allergy history with confirmed cephalosporin allergy will be presented as odds ratios with 95% confidence intervals. |
Up to 7 weeks
|
|
Proportion of nocebo responders
Lasso di tempo: Up to 7 weeks
|
The rate of nocebo response in those undergoing cephalosporin drug challenges will be measured. |
Up to 7 weeks
|
|
Cephalosporin-specific antibody levels
Lasso di tempo: Up to 54 months
|
Cephalosporin drug- and hapten-specific antibody levels will be evaluated from serum using ELISA. |
Up to 54 months
|
|
Cephalosporin-specific antibody binding
Lasso di tempo: Up to 54 months
|
Cephalosporin drug antibody binding epitopes will be presented using nanoallergens to evaluate rates of antibody binding and cell degranulation to gain a mechanistic understanding of cephalosporin allergy. |
Up to 54 months
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Prevalence of nocebo response
Lasso di tempo: Up to 7 weeks
|
The prevalence of nocebo responses to drug challenges will be measured to understand how often these responses occur during cephalosporin challenges. |
Up to 7 weeks
|
|
Graded severity of nocebo response reactions
Lasso di tempo: Up to 7 weeks
|
Respiratory, mucocutaneous, and cardiovascular symptoms and clinical presentation of nocebo response reactions will be collected and graded using the United States Drug Allergy Registry (USDAR) grading scale to determine the average severity of nocebo reactions. This scale is scored as either NR (no reaction) or values 0-4 indicating the severity of the reaction, with 0 being the mildest and 4 being the most severe. |
Up to 7 weeks
|
|
Cephalosporin skin test clinical statistics
Lasso di tempo: Up to 7 weeks
|
The average diameter size of the wheal and flare during cephalosporin skin tests will be determined. |
Up to 7 weeks
|
|
Tryptase levels in those with confirmed allergy
Lasso di tempo: Up to 7 weeks
|
In participants with confirmed cephalosporin allergy, tryptase levels will be evaluated and compared to determine if tryptase levels are associated with reaction grades. |
Up to 7 weeks
|
|
Amoxicillin cross-reactivity in those with confirmed cephalosporin allergy
Lasso di tempo: Up to 7 weeks
|
Among those with confirmed cephalosporin allergy, the proportion with cross-reactivity to amoxicillin will be determined. |
Up to 7 weeks
|
|
Amoxicillin skin test diagnostic characteristics in those with confirmed cephalosporin allergy
Lasso di tempo: Up to 7 weeks
|
Among those with confirmed cephalosporin allergy, the skin test diagnostic characteristics with amoxicillin will be determined, including positive predictive value (PPV), negative predictive value (NPV), and false positive rate. |
Up to 7 weeks
|
|
Similar cephalosporin skin test diagnostic characteristics in participants with confirmed cephalosporin allergy
Lasso di tempo: Up to 7 weeks
|
Among those with confirmed cephalosporin allergy, the skin test diagnostic characteristics with a similar side-chain cephalosporin will be determined, including positive predictive value (PPV), negative predictive value (NPV), and false positive rate. |
Up to 7 weeks
|
|
Dissimilar cephalosporin skin test diagnostic characteristics in participants with confirmed cephalosporin allergy
Lasso di tempo: Up to 7 weeks
|
Among those with confirmed cephalosporin allergy, the skin test diagnostic characteristics with a dissimilar side-chain cephalosporin will be determined, including positive predictive value (PPV), negative predictive value (NPV), and false positive rate. |
Up to 7 weeks
|
|
Graded severity of cephalosporin allergic reactions
Lasso di tempo: Up to 7 weeks
|
Respiratory, mucocutaneous, and cardiovascular symptoms and clinical presentation of cephalosporin allergic reactions will be collected and graded using the United States Drug Allergy Registry (USDAR) grading scale to determine the average severity of cephalosporin reactions. This scale is scored as either NR (no reaction) or values 0-4 indicating the severity of the reaction, with 0 being the mildest and 4 being the most severe. |
Up to 7 weeks
|
|
Proportion of delayed hypersensitivity reactions to cephalosporins
Lasso di tempo: Up to 7 weeks
|
The proportion of participants with delayed hypersensitivity reactions to cephalosporins will be recorded. |
Up to 7 weeks
|
|
Incidence of adverse events with cephalosporin diagnostic tests
Lasso di tempo: Up to 7 weeks
|
The incidence rate of allergic and nonallergic adverse events (as graded by the United States Drug Allergy Registry (USDAR) grading scale [grades NR for no reaction and then grades 0-4 with four being the most severe reaction] and National Cancer Institute's Common Terminology Criteria for Adverse Events [grades 1 to 5, with grades 1 being the mildest and grade 5 being death]) in cephalosporin skin tests and drug challenges will be determined. |
Up to 7 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: David A Khan, MD, University of Texas Southwestern Medical Center
- Investigatore principale: Kimberly G Blumenthal, MD, MSc, Mayo Clinic
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Ipersensibilità, immediata
- Disturbi indotti chimicamente
- Effetti collaterali correlati al farmaco e reazioni avverse
- Ipersensibilità
- Anafilassi
- Ipersensibilità al farmaco
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Azoli
- Fattori biologici
- Imidazoli
- Amides
- Ammine
- Etilammine
- beta-lattamici
- Lactams
- Cefalosporine
- Tiazine
- Cefaloridina
- Autacoidi
- Mediatori di infiammazione
- Monoamine biogeniche
- Amine biogeniche
- Penicilline
- Cefacetrile
- Cefdinir
- Cefepime
- Cefpodoxima
- Ceftriaxone
- Cefazolina
- Cefalexina
- Ampicillina
- Ceftazidima
- Cefurossima
- Cefotaxima
- Cefixima
- Penicillina G
- Cefadroxil
- Cefaclor
- Istamina
- Monobattami
- benzilpenicilloil G polilisina
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2024p000928
- U01AI184071 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Data will include demographics, clinical and procedure outcomes, and laboratory results. Investigators will preserve and share de-identified individual participant-level data (IPD) through submission to a controlled-access public repository. Investigators will apply the Safe Harbor method for de-identification of participant data. Participant informed consent forms will reflect this plan. To facilitate the use and interpretation of these data, the study protocol, data collection forms, case report forms, data dictionary, manual of operations, statistical analysis plan, and source code will be shared. Investigators will use Persistent Unique Identifiers (PIDs) to improve data findability across all dissemination outputs. PIDs used will include ORCID iDs for people, DOIs for outputs (e.g., datasets, protocols), and Research Resource IDentifiers (RRIDs) for resources. Investigators will also use indexed metadata to make scientific data easily findable.
Periodo di condivisione IPD
All scientific data generated from this project will be made available as soon as possible, and no later than the time of publication or the end of the funding period, whichever comes first. The duration of preservation and sharing of the data will be a minimum of 5 years after the funding period.
Criteri di accesso alla condivisione IPD
Access to the data will be shared under controlled-access conditions as required by the policies of NIH/NIAID and the Mass General Brigham (MGB), which will serve as the sIRB. In accordance with HIPAA, scientific data derived from humans will be protected through de-identification, removal of information that may be used to infer the identity and shared under controlled-access conditions as required by NIH/NIAID and MGB institutional policy.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
- ICF
- CODICE_ANALITICO
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .